HomeGeneticsConditionCerebrotendinous xanthomatosis
Back to Condition
Cerebrotendinous xanthomatosis
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Cerebrotendinous xanthomatosis

Cerebrotendinous xanthomatosis is a lipid storage disorder where cholesterol and other fats accumulate in the brain and tendons, leading to neurological and physical symptoms.

Overview

Cerebrotendinous xanthomatosis is a disorder characterized by the abnormal storage of fats (lipids) in the body. Because the body cannot break down certain forms of cholesterol effectively, these fats accumulate as fatty yellow nodules called xanthomas, most commonly in the brain and tendons.

Symptoms

  • Neurological Problems: Often developing in early adulthood, these include recurrent seizures (epilepsy), movement disorders, impaired speech (dysarthria), loss of sensation (peripheral neuropathy), dementia, hallucinations, and depression.
  • Tendon Xanthomas: Nodules form in tendons of the hands, elbows, knees, neck, and the Achilles tendon, potentially causing discomfort and reduced flexibility.
  • Other Features: Clouding of the eye lenses (cataracts), chronic diarrhea in childhood, cholestasis (reduced bile production leading to jaundice), and brittle bones prone to fracture.
  • Systemic Risks: Increased risk of cardiovascular disease or respiratory failure due to lipid accumulation in the heart or lungs.

Frequency

The worldwide incidence is estimated at 1 per million individuals. It is more common in the Moroccan Jewish population, with an incidence of 1 in 108.

Causes

Mutations in the CYP27A1 gene cause this condition. This gene produces the enzyme sterol 27-hydroxylase, which is required to break down cholesterol into bile acids. Mutations lead to the production of nonfunctional enzymes, causing the accumulation of cholestanol and bile alcohols in the blood and tissues, which form the characteristic xanthomas.

Inheritance

This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations.

Frequently Asked Questions

The first‑line therapy is oral chenodeoxycholic acid (CDCA) at 15 mg/kg/day, which suppresses the synthesis of abnormal cholestanol and reduces its accumulation. When started early, CDCA can stabilize or improve neurological symptoms, prevent new tendon xanthomas, and lower the risk of cataracts and bone disease. Regular monitoring of plasma cholestanol levels guides dose adjustments.
CTX tendon xanthomas are typically firm, yellow‑white, and located over extensor tendons (Achilles, patellar, extensor digitorum). They often appear bilaterally and may be associated with a history of early‑onset cataracts or chronic diarrhea. Ultrasound or MRI can show homogeneous, hyperechoic lesions without a capsule, distinguishing them from lipomas (which are more compressible and have a distinct capsule).
Schedule annual neurologic exams (including gait and cognitive testing), liver function tests, and plasma cholestanol measurement. Bone density scans (DEXA) every 2–3 years assess osteoporosis risk. Ophthalmologic exams for cataracts should be performed yearly, and cardiac evaluation (echocardiogram) every 3–5 years to detect lipid infiltration of the myocardium.
Because CTX is autosomal recessive, first‑degree relatives have a 25 % chance of being affected if both parents are carriers. Offer targeted genetic testing (sequencing of CYP27A1) to siblings and, if they are carriers, to their children. Testing is done via a blood sample or buccal swab, and results guide early initiation of CDCA if a mutation is identified.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab